Want to see ABCL full AI Analyst Report?

AbCellera Biologics (ABCL) Price & Analysis

2,416 Followers

ABCL Stock Chart & Stats

$4.01

-$0.28(-8.54%)

At close: Jan 08 4:00 PM EST

$4.01

-$0.28(-8.54%)

Day’s Range― - ―

52-Week Range$2.75 - $8.44

Previous CloseN/A

Volume1.71M

Average Volume (3M)7.49M

Market Cap

$2.08B

Enterprise Value$1.72B

Total Cash (Recent Filing)$504.73M

Total Debt (Recent Filing)$140.18M

Price to Earnings (P/E)―

Beta1.77

Next Earnings

Aug 05, 2026

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.48

Shares Outstanding305,375,400

10 Day Avg. Volume7,724,018

30 Day Avg. Volume7,491,781

Financial Highlights & Ratios

PEG Ratio0.64

Price to Book (P/B)1.06

Price to Sales (P/S)13.60

P/FCF Ratio-5.87

Enterprise Value/Market Cap0.83

Enterprise Value/Revenue21.77

Enterprise Value/Gross Profit27.53

Enterprise Value/Ebitda-10.94

Forecast

1Y Price Target

$9.40

Price Target Upside134.41% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-0.59

Revenue Forecast (FY)$33.21M

Bulls Say, Bears Say

Bulls Say

Strong Liquidity / RunwayA total liquidity pool of roughly $655M provides multi-year runway to fund internal clinical programs and IND‑enabling work without immediate reliance on equity markets. This supports sustained R&D cadence, reduces short‑term dilution risk, and allows deliberate prioritization of higher‑value assets.

Clear Clinical Catalyst (ABCL635)Advancing ABCL635 into Phase II with a defined Q3 2026 topline readout concentrates value‑creating potential into a near‑term, binary milestone. A positive Phase II would materially de‑risk the program, validate the platform's therapeutic approach and accelerate partner interest or internal development prioritization.

Strategic Partnership & Non‑Dilutive FundingThe preclinical collaboration with Jazz brings sizable upfront cash and large milestone upside, validating AbCellera's T‑cell engager platform. It diversifies funding sources, provides non‑dilutive capital for R&D, and offers a commercialization pathway that leverages partner resources and reduces execution burden.

Bears Say

Ongoing Cash BurnPersistent negative operating and free cash flow means the business is not yet self‑funding its R&D and operating needs. Over time this necessitates continued reliance on existing liquidity, partner payments, or future financing, which can compress strategic optionality and increase dilution or conditional deal dependency.

Sustained UnprofitabilityLarge operating and net losses, despite high gross margins and revenue growth, indicate structural cost intensity relative to current revenue scale. Until operating leverage is achieved, shareholder value is eroded and the company remains exposed to financing risk if milestone timing or partner income disappoints.

Clinical / Scientific RiskThe company's value is concentrated in a handful of early‑stage programs; until Phase II confirms clinical benefit, efficacy and generalizability remain uncertain. Blinded MAD data and limited diversity amplify risk that positive PK/PD may not translate to robust clinical outcomes, keeping program valuations binary.

AbCellera Biologics News

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

Some early-stage growth names now sit in the under-$10 range, such as AbCellera Biologics ($ABCL), Serve Robotics ($SERV),...

4d ago

ABCL

NUVB

AbCellera Biologics call volume above normal and directionally bullish

Bullish option flow detected in AbCellera (ABCL) Biologics with 3,839 calls trading, 1.1x expected, and implied vol increasing...

5d ago

ABCL

AbCellera upgraded to Buy from Hold at Benchmark

Benchmark upgraded AbCellera (ABCL) to Buy from Hold with an $11 price target. The company’s recent development agreement...

7d ago

ABCL

JAZZ

AbCellera apponts Lynn Seely to board of directors

AbCellera (ABCL) announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director....

8d ago

ABCL

LYEL

AbCellera Biologics call volume above normal and directionally bullish

Bullish option flow detected in AbCellera (ABCL) Biologics with 12,052 calls trading, 3x expected, and implied vol increasing...

20d ago

ABCL

Jazz Pharmaceuticals, AbCellera collaborate for TCE multispecific antibodies

Jazz Pharmaceuticals (JAZZ) and AbCellera (ABCL) announced a preclinical research collaboration, option and license agreement to discover and...

27d ago

ABCL

JAZZ

Jazz and AbCellera announce research collaboration for TCE antibodies

Jazz Pharmaceuticals (JAZZ) and AbCellera (ABCL) announced a preclinical research collaboration, option and license agreement to discover and...

27d ago

ABCL

JAZZ

AbCellera Biologics Adds Independent Director to Board

The latest update is out from AbCellera Biologics ( ($ABCL) ). On June 30, 2026, AbCellera Biologics Inc....

8d ago

ABCL

AbCellera, Jazz Partner on Next-Generation Cancer Antibodies

AbCellera Biologics ( ($ABCL) ) has issued an update. On June 17, 2026, Jazz Pharmaceuticals and AbCellera Biologics...

27d ago

ABCL

AbCellera Shareholders Back Directors, Auditors, Executive Pay

An announcement from AbCellera Biologics ( ($ABCL) ) is now available. AbCellera Biologics Inc. held its Annual Meeting...

1M ago

ABCL

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Critical Metals Corp (CRML)...

1M ago

JBS

ABCL

AbCellera Biologics Adds Victor Sandor to Board

AbCellera Biologics ( ($ABCL) ) just unveiled an announcement. On June 1, 2026, AbCellera Biologics appointed medical oncologist...

1M ago

ABCL

AbCellera appoints Victor Sandor to board of directors

AbCellera (ABCL) announced the appointment of Victor Sandor to its Board of Directors as an independent director. Previously,...

1M ago

ABCL

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: T-REX 2X Long BMNR...

2M ago

ALM

IRE

ABCL FAQ

What was Abcellera Biologics, Inc.’s price range in the past 12 months?

Abcellera Biologics, Inc. lowest stock price was $2.75 and its highest was $8.44 in the past 12 months.

What is Abcellera Biologics, Inc.’s market cap?

Abcellera Biologics, Inc.’s market cap is $2.08B.

When is Abcellera Biologics, Inc.’s upcoming earnings report date?

Abcellera Biologics, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 22 days.

How were Abcellera Biologics, Inc.’s earnings last quarter?

Abcellera Biologics, Inc. released its earnings results on May 11, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.171 by $0.031.

Is Abcellera Biologics, Inc. overvalued?

According to Wall Street analysts Abcellera Biologics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Abcellera Biologics, Inc. pay dividends?

Abcellera Biologics, Inc. does not currently pay dividends.

What is Abcellera Biologics, Inc.’s EPS estimate?

Abcellera Biologics, Inc.’s EPS estimate is -0.14.

How many shares outstanding does Abcellera Biologics, Inc. have?

Abcellera Biologics, Inc. has 305,375,400 shares outstanding.

What happened to Abcellera Biologics, Inc.’s price movement after its last earnings report?

Abcellera Biologics, Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.171. Following the earnings report the stock price went down -5.714%.

Which hedge fund is a major shareholder of Abcellera Biologics, Inc.?

Currently, no hedge funds are holding shares in ABCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

AbCellera Biologics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-14.86%

Trailing 12-Months

Asset Growth

-2.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Abcellera Biologics, Inc.

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

AbCellera Biologics (ABCL) Earnings & Revenues

Historic Earnings Reports

ABCL Revenue Breakdown

93.51% Research fees

3.94% Royalty revenue

2.55% Milestone payments

ABCL Stock 12 Month Forecast

Average Price Target

$9.40

▲(134.41% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","14":"$14"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5,8,11,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.6,8.015384615384615,8.430769230769231,8.846153846153847,9.26153846153846,9.676923076923076,10.092307692307692,10.507692307692308,10.923076923076923,11.338461538461537,11.753846153846155,12.169230769230769,12.584615384615384,{"y":13,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.6,7.7384615384615385,7.8769230769230765,8.015384615384615,8.153846153846153,8.292307692307693,8.430769230769231,8.569230769230769,8.707692307692309,8.846153846153847,8.984615384615385,9.123076923076923,9.261538461538462,{"y":9.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.6,7.553846153846154,7.507692307692308,7.461538461538462,7.415384615384615,7.369230769230769,7.323076923076923,7.276923076923077,7.230769230769231,7.184615384615385,7.138461538461538,7.092307692307692,7.046153846153846,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.49,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.43,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.46,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >